Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
3.690
+0.120 (3.36%)
At close: Aug 28, 2025, 4:00 PM
3.700
+0.010 (0.27%)
After-hours: Aug 28, 2025, 7:11 PM EDT
Relay Therapeutics Revenue
Relay Therapeutics had revenue of $677.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $8.36M, down -76.27% year-over-year. In the year 2024, Relay Therapeutics had annual revenue of $10.01M, down -60.83%.
Revenue (ttm)
$8.36M
Revenue Growth
-76.27%
P/S Ratio
71.58
Revenue / Employee
$32,011
Employees
261
Market Cap
636.20M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.01M | -15.54M | -60.83% |
Dec 31, 2023 | 25.55M | 24.17M | 1,749.82% |
Dec 31, 2022 | 1.38M | -1.65M | -54.41% |
Dec 31, 2021 | 3.03M | -79.63M | -96.34% |
Dec 31, 2020 | 82.65M | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
RLAY News
- 9 hours ago - Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September - GlobeNewsWire
- 21 days ago - Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 26 days ago - Relay Therapeutics: What's Next For H2 2025? - Seeking Alpha
- 4 weeks ago - Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025 - GlobeNewsWire
- 2 months ago - Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors - GlobeNewsWire
- 3 months ago - Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 - GlobeNewsWire
- 3 months ago - Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June - GlobeNewsWire
- 4 months ago - Relay Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewsWire